Also known as: FLOT
Michelle, a mental health therapist, was diagnosed with stage 4 lung cancer and given 24 months to live. Through yoga and meditation, she shifted her mindset and is now thriving six years after diagnosis, with tumors continuing to shrink.
A study in The Oncologist found that Oncotype DX testing improved overall survival in ultra-low-risk HR+ breast cancer patients, with chemotherapy further prolonging survival in high-risk cases. Genomic testing supports personalized treatment decisions.
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
UNM Comprehensive Cancer Center installs MRI-LINAC, enabling real-time tumor tracking and adaptive radiation therapy. The system has treated 10 patients and improves precision, reducing damage to healthy tissue.
ASH has published new clinical practice guidelines for frontline and relapsed/refractory ALL management in adolescents and young adults, endorsing pediatric-inspired regimens, asparaginase therapy, and immunotherapy over traditional chemotherapy.
A JAMA Otolaryngology study found most head and neck trial failures stem from strategic sponsor decisions and poor recruitment, while broader analysis shows site selection and feasibility missteps often cause trials to struggle before enrollment.
In Australia, 19 women are diagnosed daily with gynaecological cancer, and experts say late detection is the primary issue. Ovarian cancer is often caught at advanced stages, while endometrial cancer deaths are rising. Personal stories underscore the need for early symptom awareness.
The American College of Sports Medicine has published the first evidence-based exercise guidelines for children and adolescents with cancer, recommending safe, supervised activity during treatment. A new clinical trial is also evaluating structured exercise for young sarcoma patients undergoing chemotherapy to improve outcomes and quality of life.
Patients with stage 4 lung, sarcoma, and gastro-oesophageal cancer describe their experiences with targeted therapies, chemotherapy, and immunotherapy, highlighting varying outcomes and financial challenges.
The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07785180 |
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy |
RECRUITING | |
| NCT07780721 |
Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07691645 |
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome |
NOT_YET_RECRUITING | PHASE2 |
| NCT07689539 |
Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation |
NOT_YET_RECRUITING | PHASE3 |
| NCT07657130 |
Optimal Application Timing of ADC Drugs for Advanced Breast Cancer |
RECRUITING | PHASE2 |
| NCT07637851 |
Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07627620 |
Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07620548 |
Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas |
NOT_YET_RECRUITING | PHASE2 |
| NCT07613151 |
Negative/Low Hormone Receptor and APOcrine Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study |
RECRUITING | |
| NCT07602140 |
TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study. |
NOT_YET_RECRUITING | PHASE2 |
